BioMarin Pharmaceutical Inc. announced that new data on VOXZOGO®? in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology Meeting in The.
BioMarin Pharma (BMRN) Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO to Treat Children Aged 4 Months and Older with Achondroplasia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
European Commission Approval Decision Expected Q4 2023
Opinion Based on Positive Results from Global Phase 2 and Ongoing Extension Study
U.S. Food and Drug Administration PDUFA Target Action Date.
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.